Business Wire

Prometheus Materials’ Bio-Cement and Bio-Concrete Achieves 12x the Sound Absorption of Traditional Concrete in ASTM Testing

2.8.2023 15:00:00 EEST | Business Wire | Press release

Share

Prometheus Materials, a leader in sustainable building materials, announced today the achievement of remarkable results in the ASTM C423 sound-absorption testing of its ground-breaking bio-cement and bio-concrete technology. The company develops revolutionary zero-carbon building solutions that provide a superior alternative to carbon-intensive portland cement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230802310284/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Prometheus Materials' superior sound-absorption performance compared to traditional concrete (Graphic: Business Wire)

The Johns Manville Technical Center in Littleton, Colorado – a world-class research and development facility – conducted the independent testing, which found that Prometheus Materials’ bio-concrete demonstrated a Noise Reduction Coefficient (NRC) of 0.60. This NRC rating indicates 60% sound absorption – twelve times that of traditional concrete.

Prometheus Materials’ initial pre-cast bio-concrete product line includes masonry units, segmented modular block and acoustic panels – where this exceptional sound-absorption characteristic will be an essential feature – as well as paving stones and grass pavers. These products are currently available strictly for select projects, with commercial availability slated for the first half of 2024.

Such unrivaled sound absorption is a cost-saving, environment-enhancing boon for various sectors. In settings where noise can be damaging or distracting, builders are often forced to rely on secondary products to achieve some measure of noise reduction. Beyond the added expense, these materials can sometimes have negative effects – including health risks. However, with Prometheus Materials’ bio-cement and bio-concrete products, such facilities can incorporate sound-absorption capabilities without additional cost, safety concerns or other drawbacks. Residential, commercial and institutional buildings, amphitheaters, music studios, highway barriers – and a vast array of other end-uses – will all benefit from this exceptional noise-reduction capability, while concurrently reducing their carbon footprint.

“Our latest ASTM testing results embody our commitment to innovative design,” said Loren Burnett, President, CEO & Co-founder of Prometheus Materials. “We’ve developed a novel material that provides a zero-carbon alternative to traditional concrete while delivering additional performance benefits and applications. We’re proud to pave the way toward a more technologically advanced and environmentally responsible future for the construction industry.”

Vishaan Chakrabarti, FAIA FRAIC – renowned architect, academic and business leader with focus on sustainable design; Founder and Creative Director of Practice for Architecture & Urbanism (PAU); and member of Prometheus Materials’ Board of Directors – was equally inspired. “Test results like these prove that Prometheus Materials has developed far more than zero-carbon concrete – which by itself is an enormous accomplishment,” he said. “With this level of sound absorption, as well as other characteristics currently being tested, it's clear that this material will offer a suite of products based on entirely redefined ideas of what concrete can be and do.”

Prometheus Materials continues to lead the charge in sustainability and innovation within the building materials sector. With these ASTM C423 sound-absorption results joining its previously secured ASTM C129 and C90 certifications – plus other features of its bio-cement and bio-concrete that are comparable or superior to traditional concrete – the company is poised to drive the construction industry toward a more cutting-edge and sustainable future.

About Prometheus Materials

Prometheus Materials provides sustainable building materials that accelerate the world’s transition to a carbon-negative future. Inspired by biological processes found in nature, the company’s process uses microalgae to produce a bio-cement that offers an alternative to carbon-intensive portland cement. When mixed with aggregate, this bio-cement forms a zero-carbon bio-concrete with mechanical, physical and thermal properties that rival those of portland cement-based concrete. Learn more about how the company enables the decarbonization of the construction industry at prometheusmaterials.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Liz Crumpacker
Antenna Group
prometheus@antennagroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB to Host 2026 Digital Investor Day10.6.2026 15:30:00 EEST | Press release

SLB (NYSE: SLB) will host an Investor Day on Wednesday, June 17, 2026, in New York, where leadership will outline their vision for SLB’s Digital business as digital technologies and AI continue to reshape the energy industry. The presentation will highlight SLB’s integrated digital strategy and portfolio, scalable growth opportunities powered by AI, and financial profile and outlook. Olivier Le Peuch, chief executive officer, SLB, will present at 9:00 a.m. U.S. Eastern Time (ET), and will discuss SLB’s digital strategy and business outlook. Stephane Biguet, chief financial officer, SLB, will present at approximately 11:00 a.m. ET, and will discuss the financial profile of SLB’s Digital business, the market opportunity and SLB’s 2030 digital ambitions. Mr. Le Peuch and Mr. Biguet will be joined by divisional leadership, who will provide further insight into Digital’s competitive differentiation supported by its mission-critical platform, driving transformation for customers. A live webc

Macrobond Launches AI Data Feed with MCP and Skill, Bringing Governed Macroeconomic Intelligence to Enterprise AI Workflows10.6.2026 15:00:00 EEST | Press release

Macrobond today announced the general availability of the Macrobond AI Data Feed Service, a purpose-built product, enabling financial institutions to integrate governed macroeconomic intelligence directly into AI-powered research, investment, and strategy workflows. Available now with MCP, Skill and API delivery components, the AI Data Feed helps organizations accelerate macroeconomic research and insight generation and reduce reliance on fragmented or ungoverned data sources. By delivering reliable, licensed, economic data integrated directly within AI chat interfaces and coding environments, the AI Data Feed Service provides a trusted foundation for enterprise AI initiatives. As generative AI becomes embedded in research, investment, and strategy workflows, face a foundational challenge: most AI systems operate on ungoverned data producing outputs that are difficult to trust, reproduce, or audit. The Macrobond AI Data Feed Service directly addresses this gap by connecting customer’s

Wolters Kluwer expands its Libra AI workspace with authoritative Swiss legal content from leading publisher Stämpfli10.6.2026 15:00:00 EEST | Press release

Wolters Kluwer Legal & Regulatory today announced the expansion of Libra by Wolters Kluwer, its AI-powered legal workspace, to include professional legal content from Stämpfli Publishers, one of Switzerland’s most respected legal publishers. As a result, Swiss legal professionals using Libra by Wolters Kluwer gain direct access to the legal literature that shapes their daily work – fully integrated into a single AI-supported workflow. The content offering includes commentaries, practitioner guides, yearbooks and selected journals from Stämpfli Publishers – including the renowned “Berner Kommentar”, and the company’s succinct commentaries and legal textbooks. In addition, primary sources of Swiss law at both federal and cantonal level are integrated into the workspace. The offering will be continuously expanded over time, with additional titles gradually integrated into the working environment. Libra by Wolters Kluwer provides a fully integrated and secure working environment in which l

Parse Biosciences Launches the Next Generation of its Immune Profiling Kits10.6.2026 15:00:00 EEST | Press release

Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today launched the next generation of its Evercode™ TCR and Evercode™ BCR kits, shipping to customers worldwide. The updated kits deliver a streamlined workflow, better whole transcriptome sequencing library efficiency, and improved performance, enabling researchers to resolve rare clonotypes and profile immune responses at unprecedented scale. Immunology researchers are working to understand complex adaptive immune responses, but meaningful signals are often rare, transient, or difficult to capture across large, sample-limited studies. Parse's immune profiling portfolio combines scale, sensitivity, and fixation-first workflows with paired TCR or BCR and whole transcriptome profiling, helping researchers connect clonal identity to cell state across high-throughput immune studies. Both Evercode TCR and Evercode BCR are now built on the same v4 chemistry that powers the latest Evercode Wh

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region10.6.2026 14:47:00 EEST | Press release

GENESIS Pharma, a leading regional biopharma company focused on the commercialization of innovative medicines in Europe, today announced the expansion of its longstanding commercial partnership with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), the leading RNAi therapeutics company. The extended agreement broadens the geographical reach of the collaboration to include four Nordic markets -Denmark, Finland, Norway, and Sweden- alongside the thirteen markets in Southeast Europe already within the scope of the partnership. GENESIS Pharma shall commercialize a portfolio of RNAi therapeutics for serious cardiomyopathy conditions and rare genetic diseases across this expanded territory. The partnership, established in 2019 for Southeast Europe, has progressively evolved to encompass a broader portfolio and geographic footprint, covering Greece, Cyprus, Bulgaria, Romania, Slovenia, Croatia, Serbia, Bosnia and Herzegovina, Albania, the Republic of North Macedonia, Montenegro, Malta, and Kosovo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye